Diamond Biotechnology Co., Ltd reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 192.89 million compared to TWD 153.56 million a year ago. Net income was TWD 17.34 million compared to net loss of TWD 4.33 million a year ago.

Basic earnings per share from continuing operations was TWD 0.6992 compared to basic loss per share from continuing operations of TWD 0.1737 a year ago. Diluted earnings per share from continuing operations was TWD 0.6992 compared to diluted loss per share from continuing operations of TWD 0.1737 a year ago.